Role of infection and inflammation in development of atherosclerosis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The present report reviews the current status of knowledge regarding the role of infectious agents and of inflammatory mediators in the development of atherosclerosis. Inflammation in the arterial vessel wall is considered to play an important role in the pathogenesis of atherosclerosis. Clinical studies affirm correlation of circulating markers of inflammation with propensity to develop ischemic events. The candidate trigger of inflammatory response is chronic or acute infection. The relationship between infection and atherogenesis is extremely complex. The study results are very contradictory, mainly due to methodological causes. It also appears that the aggregate number of certain pathogens (“pathogen burden”) with which an individual is infected, rather than any individual pathogen, will determine the infection-related propensity to develop atherosclerosis and the infection-related likelihood of a patient’s course.

About the authors

Yu. V. Lobzin

Russian Military Medical Academy

Author for correspondence.
Email: shabanov@mail.rcom.ru

член-корреспондент РАМН

Russian Federation, St. Petersburg, 194175

A. V. Rudakova

Russian Military Medical Academy

Email: shabanov@mail.rcom.ru
Russian Federation, St. Petersburg, 194175

References

  1. Albert M. A., Danielson E., Rifai N. et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation / CRP evaluation (PRINCE): a randomized trial and cohort study // JAMA. 2001. Vol. 2 86. P. 64-70.
  2. Anderson J. L., Carlquist J.E, Muhlestein J. B. et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction // J. Am. Coll. Cardiol. 1998. Vol. 32. P. 35-41.
  3. Benditt E. P, Benditt J. M. Evidence for monoclonal origin of atherosclerosis // Proc. Natl. Acad. Sci. USA. 1973. Vol. 70. P. 1753-1756.
  4. Bhatt D. L., Topol E. J. Need to test the arterial inflammation hypothesis // Circulation. 2002. Vol. 106. P. 136-140.
  5. Biasucci L. M., Liuzzo G., Grillo R. L. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability // Circulation. 1999. Vol. 99. P. 855-860.
  6. Buffon A., Liuzzo G., Biasucci L. M. et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty // J. Am. Coll. Cardiol. 1999. Vol. 34. P. 1512-1521.
  7. Chae C. U., Lee R. T., Rifai N. et al. Blood pressure and inflammation in apparently healthy men // Hypertension. 2001. Vol. 3 8. P. 399—403.
  8. Chew D. R, Bhatt D. L., Robbins M. A. et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein // Am. J. Cardiol. 2001. Vol. 88. P. 672-674.
  9. Di Napoli M., Papa E., Bocola V. C-reactive protein in ischemic stroke: an independent prognostic factor// Stroke. 2001. Vol. 32. P. 917-924.
  10. Doo Y, Kim D., Oh D. et al. Effect of beta-blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris // Am. J. Cardiol. 2001. Vol. 88. P. 422-424.
  11. Espinola-Klein C., Rupprecht H. J., Blankenberg S. et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis // Circulation. 2002. Vol. 105. P. 15-21.
  12. Fabricant C. G., Fabrican J., Litrenta M. M. et al. Virus-induced atherosclerosis // J. Exp. Med. 1978. Vol. 148. P. 335-340.
  13. Frothingham C. The relationship between acute infectious diseases and arterial lesions // Arch. Intern. Med. 1911. Vol. 8. P. 153-162.
  14. Guillevin L., Lhote F., Gherardi R. The spectrum and treatment of virus-associated vasculitides // Curr. Opin. Rheumatol. 1997. Vol. 9. P 31-36.
  15. Gupta S., Leatham E. W., Carrington D. et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction // Circulation. 1997. Vol. 96. P. 404-407.
  16. Gurfinkel E., Bozovich G., Beck E. et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study // Eur. Heart J. 1999. Vol. 20. P. 121-127.
  17. Hernandez-Presa M. A., Bustos C., Ortego M. et al. ACE inhibitor quinapril reduces the arterial expression of NF-kB-dependent proinflammatory factors but not of collagen 1 in a rabbit model of atherosclerosis // Am. J. Pathol. 1998. Vol. 153. P. 1825-1837.
  18. Ikonomidis I., Andreotti F., Economou E. et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin // Circulation. 1999. Vol. 100. P. 793-798.
  19. Ishizaka N., Ishizaka Y., Takahashi E. et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers // Circulation. 2002. Vol. 105. P. 1028-1030.
  20. Jackson L. A., Yu O., Heckbert S. R. et al. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events // Am. J. Epidemiol. 2002. Vol. 156. P. 634-640.
  21. Jialal I., Stein D., Balis D. et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels // Circulation. 2001. Vol. 103. P. 1933-1935.
  22. Katritsis D., Korovesis S., Giazitoglou E. et al. C-reactive protein concentrations and angiographic characteristics of coronary lesions // Clin Chem. 2001. Vol. 47. P. 882-886.
  23. Kiechl S., Egger G., Mayr M. et al. Chronic infections and the risk of carotid atherosclerosis // Circulation. 2001. Vol. 103. P. 1064-1070.
  24. Kowalski M., Konturek P. C., Pieniazek P. et al. Prevalence of Helicobacter pylori infection in coronary artery disease and effect of its eradication on coronary lumen reduction after percutaneous coronary angioplasty // Digest. Liver Dis. 2001. Vol. 3 3. P. 222-229.
  25. Kreis berg R. A., Oberman A. Lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies // J. Clin. Endocrinol. Metab. 2002. Vol. 87. P. 423-437.
  26. LaBiche R., Koziol D., Quinn T. et al. Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque // Stroke. 2001. Vol. 32. P. 855-860.
  27. Libby P., Ridker PM., Maseri A. Inflammation and atherosclerosis // Circulation. 2002. Vol. 105. P. 1135-1143.
  28. Mason A., Wick M., White H. et al. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection // Hepatology. 1993. Vol. 18. P. 781-789.
  29. Mayr M., Kiechl S., Willeit J. et al. Infections, immunity, and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis // Circulation. 2000. Vol. 102. P. 83 3-83 9.
  30. Melissano G., Blasi E., Esposito G. et al. Chlamydia pneumoniae eradication from carotid plaques: results of an open, randomized treatment study // Eur. J. Vasc. Endovasc. Surg. 1999. Vol. 18. P. 355-359.
  31. Muhlestein J. B., Anderson J. L., Cartquist J. E. et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study // Circulation. 2000. Vol. 102. P. 1755-1760.
  32. Naghavi M., Barias Z., Siadaty S., Naguib S. et al. Association of influenza vaccination and reduced risk of recurrent myocardial infarction // Circulation. 2000. Vol. 102. P. 3039-3045.
  33. Neumann E J. Chlamydia pneumoniae — atherosclerosis link // Circulation. 2002. Vol. 106. P. 2414-2416.
  34. Neumann E J., Kastrati A., Miethke T. et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect of neointima proliferation after coronary stent placement (ISAR-3): a randomized, double-blind, placebo- controlled trial // Lancet. 2001. Vol. 357. P. 2085-2089.
  35. Parchure N., Zouridakis E., Kaski J. C. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection // Circulation. 2002. Vol. 105. P. 1298-1303.
  36. Prager M., Ture I. Z., Speidl W et al. Chlamydia pneumoniae in carotid artery atherosclerosis. A comparison of its presence in atherosclerotic plaque, healthy vessels, and circulating leukocytes from the same individuals // Stroke. 2002. 10.1161/01. STR.0000039322.66575.77.
  37. Prasad A., Zhu J., Halcox J. et al. Predisposition to atherosclerosis by infections // Circulation. 2002. Vol. 106. P. 184-190.
  38. Ridker PM., Rifai N., Clearfield M. et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events // N. Engl. J. Med. 2001. Vol. 344. P. 1959-1965.
  39. Ridker P. M., Rifai N., Lowenthal S. P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia // Circulation. 2001. Vol. 103. P. 1191-1193.
  40. Ridker P.M., Rifai N., Pfeffer M. et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels // Circulation. 1998. Vol. 98. P. 839-844.
  41. Ridker P M., Rifai N., Pfeffer M. A. et al. Longterm effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators // Circulation. 1999. Vol. 100. P. 230-235.
  42. Rupprecht H.J., Blankenberg S., Bickel C. et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease // Circulation. 2001. Vol. 104. P. 25-31.
  43. Sander D., Winbeck K., Klingelhofer J. et al. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity // Circulation. 2001. Vol. 103. P. 1390-1395.
  44. Sander D., Winbeck K., Klingelhofer J. et al. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity // Circulation. 2002. Vol. 106. P. 2428-2433.
  45. Sinisalo J., Mattila K., Valtonen V. et al. Effect of 3 months antimicrobial treatment with Clarithromycin in acute non-Q-wave coronary syndrome // Circulation. 2002. Vol. 105. P. 1555-1560.
  46. Stone A., Mendall M., Kaski J.-C. et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes // Circulation. 2002. Vol. 106. P. 1219-1223.
  47. Sumida Y., Nakashima T., Yoh T. et al. Serum thioredoxin elucidates the significance of serum ferritin as a marker of oxidative stress in chronic liver diseases // Liver. 2001. Vol. 21. P. 295-299.
  48. Wiesli P, Czerwenka W., Meniconi A. et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men // Circulation. 2002. Vol. 105. P. 2646-2652.
  49. Zhu J., Niieto F. J., Horne B. D. et al. Prospective study of pathogen burden and risk of myocardial infarction or death // Circulation. 2001. Vol. 103. P. 45-51.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2003 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.